Evidence map›Paper›PMID 34513055›Full record

ArticleSovremennye tekhnologii v meditsine2020

The Mechanism of Action of Ethoxidol on Oxidative Stress Indices in Heart Failure and Hypotension.

V G Kukes, O K Parfenova, B K Romanov, A B Prokofiev, E V Parfenova, N G Sidorov, A A Gazdanova, L I Pavlova, V I Zozina, A D Andreev and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

V G KukesAcademician of the Russian Academy of Sciences, Professor, Department of Clinical Pharmacology and Propedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia; Head of the Scientific Direction "Pharmacology", Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, 8, Bld. 2, Petrovsky Boulevard, Moscow, 127051, Russia.
O K ParfenovaStudent, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
B K RomanovDeputy Director General on Scientific Work, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, 8, Bld. 2, Petrovsky Boulevard, Moscow, 127051, Russia.
A B ProkofievProfessor, Department of Clinical Pharmacology and Propedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia; Director of the Clinical Pharmacology Center, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, 8, Bld. 2, Petrovsky Boulevard, Moscow, 127051, Russia.
E V ParfenovaProfessor, Corresponding Member of the Russian Academy of Sciences, Deputy Director General, National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, 15A 3 Cherepkovskaya St., Moscow, 121552, Russia; Director of the Institute of Experimental Cardiology, National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, 15A 3 Cherepkovskaya St., Moscow, 121552, Russia.
N G SidorovStudent, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
A A GazdanovaAssociate Professor, Department of Clinical Pharmacology and Propedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
L I PavlovaAssociate Professor, Department of Clinical Pharmacology and Propedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
V I ZozinaPhD Student, Department of Clinical Pharmacology and Propedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
A D AndreevStudent, Medical Faculty, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
T V AleksandrovaSenior Analyst, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, 8, Bld. 2, Petrovsky Boulevard, Moscow, 127051, Russia.
S V ChernovaAssociate Professor, Department of Pharmaceutical and Toxicological Chemistry named after A.P. Arzamastsev, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
G V RamenskayaDirector, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia; Head of the Department of Pharmaceutical and Toxicological Chemistry named after A.P. Arzamastsev, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Malaya Trubetskaya St., Moscow, 119991, Russia.
Sechenov University · RUFederal State Budgetary Institution "Center for Expertise and Quality Control of Medical Care" · RUNational Medical Research Center of Cardiology · RURussian Scientific Center of Surgery · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MATERIALS AND

methods126 patients with FC I-III CHF have been examined. In addition to their individual therapy these patients received intravenous infusions of Ethoxidol. Blood content of 2,3-diphosphoglycerate (2,3-DPG), oxygen tension (рО

resultsIn patients with FC I, II, III CHF, on day 7 after intravenous Ethoxidol infusion at a dose of 100 mg/day, statistically significant growth (p=0.0002) of PaO

conclusionThe increased concentrations of active oxygen forms have been established to negatively affect various bodily functions and adversely influence the pathophysiology of numerous diseases. Application of antioxidants, including Ethoxidol presented by us in this article, may become a clue to the development of preventive measures for many serious diseases.

Indexed as

active forms of oxygenantioxidantsheart failurehypertensiontelomeres

Identifiers

PMID34513055
PMCPMC8353682
OpenAlexW3023130955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.